Novo Nordisk (NVO) Fell Following a Profit Warning Release

Parnassus Investments, an concern absorption firm, released its “Parnassus Value Equity Fund” third-quarter 2025 capitalist letter. A transcript of the missive tin beryllium downloaded here. The money focuses connected owning a concentrated portfolio of U.S. large-cap stocks. For the 3rd 4th of 2025, the money reported a nett instrumentality of 7.46% outperforming its benchmark, the Russell 1000 Value Index, which returned 5.33% for the aforesaid period. During the quarter, the portfolio reduced its value successful the IT assemblage to summation holdings successful the Health Care sector. The fund’s apical 5 holdings are besides listed successful the letter, showing the firm’s main concern positions heading into 2025.

In its third-quarter 2025 capitalist letter, Parnassus Value Equity Fund highlighted stocks specified arsenic Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages successful the probe and development, manufacture, and organisation of pharmaceutical products. The one-month instrumentality of Novo Nordisk A/S (NYSE:NVO) was -0.36%, and its shares mislaid 53.82% of their worth implicit the past 52 weeks. On December 17, 2025, Novo Nordisk A/S (NYSE:NVO) banal closed astatine $47.77 per share, with a marketplace capitalization of $212.265 billion.

Parnassus Value Equity Fund stated the pursuing regarding Novo Nordisk A/S (NYSE:NVO) successful its 3rd 4th 2025 capitalist letter:

"Novo Nordisk A/S (NYSE:NVO) shares declined aft the institution issued a nett informing amid rising contention successful the obesity cause market. We support our condemnation owed to the company’s semipermanent pipeline, with imaginable catalysts successful its oral GLP-1 launch."

Novo Nordisk A/S (NYSE:NVO) is not connected our database of 30 Most Popular Stocks Among Hedge Funds. As per our database, 50 hedge money portfolios held Novo Nordisk A/S (NYSE:NVO) astatine the extremity of the 3rd quarter, which was 45 successful the erstwhile quarter. While we admit the imaginable of Novo Nordisk A/S (NYSE:NVO) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

In another article, we covered Novo Nordisk A/S (NYSE:NVO) and shared GreensKeeper Asset Management's views connected the company. In addition, delight cheque retired our hedge money capitalist letters Q3 2025 page for much capitalist letters from hedge funds and different starring investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.